These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 33028568)
1. Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor. Miwa M; Nakajima M; Kaszynski RH; Goto H BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33028568 [TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report. Lee IH; Ahn DJ Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295 [TBL] [Abstract][Full Text] [Related]
3. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases]. Menghoum N; Oriot P; Hermans MP; Mariage JL Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073 [TBL] [Abstract][Full Text] [Related]
4. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy. Dull RB; Spangler ML; Knezevich EL; Lau BM J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389 [TBL] [Abstract][Full Text] [Related]
5. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors]. Valek R; Von der Mark J Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094 [TBL] [Abstract][Full Text] [Related]
7. An Unusual Case of Metabolic Acidosis: Clinical Case Education. Abu-Amer N; Dinour D; Mini S; Beckerman P Isr Med Assoc J; 2019 Nov; 21(11):766-768. PubMed ID: 31713370 [No Abstract] [Full Text] [Related]
8. Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor. Zhang L; Tamilia M CMAJ; 2018 Jun; 190(25):E766-E768. PubMed ID: 29941433 [No Abstract] [Full Text] [Related]
9. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature. Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331 [TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Burke KR; Schumacher CA; Harpe SE Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088 [TBL] [Abstract][Full Text] [Related]
11. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Wan Azman SS; Sukor N; Abu Shamsi MY; Ismail I; Kamaruddin NA Front Endocrinol (Lausanne); 2022; 13():867647. PubMed ID: 35712244 [TBL] [Abstract][Full Text] [Related]
12. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085 [TBL] [Abstract][Full Text] [Related]
13. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. Horii T; Oikawa Y; Atsuda K; Shimada A J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127 [TBL] [Abstract][Full Text] [Related]
14. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report. Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282 [TBL] [Abstract][Full Text] [Related]
15. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182 [TBL] [Abstract][Full Text] [Related]
16. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Bamgboye AO; Oni IO; Collier A Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632 [TBL] [Abstract][Full Text] [Related]
17. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Diaz-Ramos A; Eilbert W; Marquez D Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052 [TBL] [Abstract][Full Text] [Related]
18. Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report. Klinkner G; Steingraber-Pharr M AACN Adv Crit Care; 2023 Mar; 34(1):27-32. PubMed ID: 36877649 [TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report. Yii ESS; Azli AW; Sitaram PN J Med Case Rep; 2022 Jan; 16(1):17. PubMed ID: 34983625 [TBL] [Abstract][Full Text] [Related]